Oclacitinib Maleate

N/A

Report date: 2025/12/19 13:51:13
NME

Base Information

Drug NameOclacitinib Maleate
Drug Alias NameJanus kinase 3 inhibitors (Pfizer)oclacitinibJAK3 inhibitors (Pfizer)CP-599083UK-681560 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK3
Therapy Area/IndicationsInflammationRespiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsInflammationRespiratory Distress Syndrome, Adult

Other Information

ATC CodeN/A
Related LinksN/A